New York State Common Retirement Fund trimmed its position in Immunomedics, Inc. (NASDAQ:IMMU) by 1.0% during the 4th quarter, Holdings Channel reports. The firm owned 184,056 shares of the biopharmaceutical company’s stock after selling 1,771 shares during the period. New York State Common Retirement Fund’s holdings in Immunomedics were worth $2,626,000 at the end of the most recent quarter.

A number of other large investors have also recently bought and sold shares of the business. BlackRock Inc. boosted its holdings in Immunomedics by 8.7% in the 3rd quarter. BlackRock Inc. now owns 12,203,782 shares of the biopharmaceutical company’s stock valued at $254,206,000 after purchasing an additional 974,954 shares during the last quarter. Janus Henderson Group PLC raised its stake in shares of Immunomedics by 13.1% in the 3rd quarter. Janus Henderson Group PLC now owns 3,640,299 shares of the biopharmaceutical company’s stock valued at $75,827,000 after acquiring an additional 422,540 shares during the period. Foresite Capital Management III LLC raised its stake in shares of Immunomedics by 5.9% in the 3rd quarter. Foresite Capital Management III LLC now owns 2,691,729 shares of the biopharmaceutical company’s stock valued at $56,069,000 after acquiring an additional 150,000 shares during the period. Jennison Associates LLC raised its stake in shares of Immunomedics by 14.3% in the 4th quarter. Jennison Associates LLC now owns 2,471,401 shares of the biopharmaceutical company’s stock valued at $35,267,000 after acquiring an additional 309,886 shares during the period. Finally, Nexthera Capital LP raised its stake in shares of Immunomedics by 5.2% in the 3rd quarter. Nexthera Capital LP now owns 1,398,577 shares of the biopharmaceutical company’s stock valued at $29,132,000 after acquiring an additional 69,473 shares during the period. Institutional investors own 84.63% of the company’s stock.

A number of equities research analysts have recently issued reports on IMMU shares. Wells Fargo & Co downgraded shares of Immunomedics from an “outperform” rating to a “market perform” rating and reduced their price target for the company from $44.00 to $18.00 in a research note on Friday, January 18th. ValuEngine raised shares of Immunomedics from a “buy” rating to a “strong-buy” rating in a research note on Thursday, March 14th. Piper Jaffray Companies reduced their price target on shares of Immunomedics to $20.00 and set an “overweight” rating on the stock in a research note on Tuesday, January 22nd. Jefferies Financial Group set a $21.00 price target on shares of Immunomedics and gave the company a “buy” rating in a research note on Friday, January 18th. Finally, Cowen reissued a “buy” rating and issued a $30.00 price target on shares of Immunomedics in a research note on Friday, January 18th. Two equities research analysts have rated the stock with a hold rating, eight have issued a buy rating and two have issued a strong buy rating to the company’s stock. The stock presently has an average rating of “Buy” and a consensus target price of $28.00.

Shares of IMMU opened at $18.35 on Thursday. Immunomedics, Inc. has a fifty-two week low of $11.55 and a fifty-two week high of $27.33. The company has a market cap of $3.58 billion, a P/E ratio of -17.82 and a beta of 2.08. The company has a current ratio of 13.45, a quick ratio of 13.45 and a debt-to-equity ratio of 0.06.

TRADEMARK VIOLATION WARNING: This article was first reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are viewing this article on another site, it was copied illegally and reposted in violation of US & international copyright & trademark laws. The correct version of this article can be viewed at https://www.thecerbatgem.com/2019/03/21/immunomedics-inc-immu-holdings-trimmed-by-new-york-state-common-retirement-fund.html.

Immunomedics Profile

Immunomedics, Inc, a clinical-stage biopharmaceutical company, develops monoclonal antibody-based products for the targeted treatment of cancer. Its advanced antibody-drug conjugates are sacituzumab govitecan and labetuzumab govitecan, which are in advanced trials for various solid tumors and metastatic colorectal cancer, respectively.

Recommended Story: Cost of Equity For A Business, Investors

Want to see what other hedge funds are holding IMMU? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Immunomedics, Inc. (NASDAQ:IMMU).

Institutional Ownership by Quarter for Immunomedics (NASDAQ:IMMU)

Receive News & Ratings for Immunomedics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Immunomedics and related companies with MarketBeat.com's FREE daily email newsletter.